Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice

Diabetes. 2013 Mar;62(3):711-20. doi: 10.2337/db12-0259. Epub 2012 Nov 8.

Abstract

Impaired skeletal muscle fatty acid oxidation has been suggested to contribute to insulin resistance and glucose intolerance. However, increasing muscle fatty acid oxidation may cause a reciprocal decrease in glucose oxidation, which might impair insulin sensitivity and glucose tolerance. We therefore investigated what effect inhibition of mitochondrial fatty acid uptake has on whole-body glucose tolerance and insulin sensitivity in obese insulin-resistant mice. C57BL/6 mice were fed a high-fat diet (60% calories from fat) for 12 weeks to develop insulin resistance. Subsequent treatment of mice for 4 weeks with the carnitine palmitoyltransferase-1 inhibitor, oxfenicine (150 mg/kg i.p. daily), resulted in improved whole-body glucose tolerance and insulin sensitivity. Exercise capacity was increased in oxfenicine-treated mice, which was accompanied by an increased respiratory exchange ratio. In the gastrocnemius muscle, oxfenicine increased pyruvate dehydrogenase activity, membrane GLUT4 content, and insulin-stimulated Akt phosphorylation. Intramyocellular levels of lipid intermediates, including ceramide, long-chain acyl CoA, and diacylglycerol, were also decreased. Our results demonstrate that inhibition of mitochondrial fatty acid uptake improves insulin sensitivity in diet-induced obese mice. This is associated with increased carbohydrate utilization and improved insulin signaling in the skeletal muscle, suggestive of an operating Randle Cycle in muscle.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Obesity Agents / therapeutic use*
  • Carbohydrate Metabolism / drug effects
  • Carnitine O-Palmitoyltransferase / antagonists & inhibitors*
  • Carnitine O-Palmitoyltransferase / metabolism
  • Cell Membrane / drug effects
  • Cell Membrane / metabolism
  • Diet, High-Fat / adverse effects
  • Enzyme Inhibitors / therapeutic use*
  • Glucose Intolerance / etiology
  • Glucose Intolerance / prevention & control
  • Glucose Transporter Type 4 / metabolism
  • Glycine / analogs & derivatives
  • Glycine / therapeutic use
  • Insulin Resistance*
  • Lipid Metabolism / drug effects*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria, Muscle / drug effects*
  • Mitochondria, Muscle / enzymology
  • Mitochondria, Muscle / metabolism
  • Muscle, Skeletal / drug effects
  • Muscle, Skeletal / enzymology
  • Muscle, Skeletal / metabolism
  • Obesity / drug therapy*
  • Obesity / etiology
  • Obesity / metabolism
  • Obesity / physiopathology
  • Random Allocation
  • Signal Transduction / drug effects

Substances

  • Anti-Obesity Agents
  • Enzyme Inhibitors
  • Glucose Transporter Type 4
  • Slc2a4 protein, mouse
  • 4-hydroxyphenylglycine
  • Carnitine O-Palmitoyltransferase
  • Glycine